Loading stock data…
PAVmed Inc. engages in acquiring (PAVM)
$4.72-0.56 (-10.61%)
Market ClosedLast close Sep 8
PAVmed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PAVmed Inc. in the Healthcare sector is trading at $4.72 with a market capitalization of $35M. Wall Street consensus targets $36.50 (2 analysts), implying a +673.3% move over the next 12 months. The stock is currently near its 52-week low of $3.85, remaining 38.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +673.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22,000↓ | $52,000↑ | $5,000↓ | $6,000↓ | $8,000 |
| Gross Profit | -$75,000↓ | -$33,000↑ | -$50,000↓ | -$35,000↓ | -$28,000 |
| Operating Income | -$7.87M↓ | -$6.65M↓ | -$4.68M↓ | -$4.63M↑ | -$5.43M |
| Net Income | -$60,000↑ | -$1.26M↑ | -$5.38M↑ | -$11.92M↓ | $18.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for u...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.13%
Volume
Today's trading volume
98,940
Recent News
PAVmed (PAVM) Q2 2026 Earnings Call Transcript
PortIO data may enable faster 510(k) pathway instead of De Novo route.
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing Losses and Strategic Progress ...
PAVmed Inc (PAVM) reports a significantly reduced net loss, advances the VARIS commercial launch at Ohio State, and explores a faster 510(k) pathway for PortIO.
PAVmed Inc. Q2 2026 Earnings Call Summary
Moby summary of PAVmed Inc.'s Q2 2026 earnings call
How The PAVmed (PAVM) Narrative Is Shifting With Reworked Assumptions And A Lower Price Target
PAVmed’s latest analyst update keeps fair value unchanged at US$40.50 but comes alongside a US$44 cut to the price target that has drawn fresh attention. Analysts frame this move as a recalibration tied to updated assumptions rather than a reaction to a single headline, which affects how the signal may be interpreted. Looking ahead, these shifting targets can be viewed within a broader narrative that investors may track over time. Stay updated as the Fair Value for PAVmed shifts by adding it...
PAVmed Inc. Q1 2026 Earnings Call Summary
Moby summary of PAVmed Inc.'s Q1 2026 earnings call